- cafead Nov 14, 2019 at 10:22: AM
via AstraZeneca’s R&D group doesn’t take failure lying down.
Hit with pivotal setbacks for their MEK 1/2 inhibitor selumetinib in several cancer studies, they regrouped and included it in their $8.4 billion alliance with Merck as the therapy was steered into a Phase II for rare cases of neurofibromatosis type 1, or NF1.
article source
Hit with pivotal setbacks for their MEK 1/2 inhibitor selumetinib in several cancer studies, they regrouped and included it in their $8.4 billion alliance with Merck as the therapy was steered into a Phase II for rare cases of neurofibromatosis type 1, or NF1.
article source